DHA supplementation for late onset Stargardt disease: NAT-3 study

BACKGROUND: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD). METHODS: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BC...

Full description

Saved in:
Bibliographic Details
Main Authors: Querques, Giuseppe, Benlian, Pascale, Chanu, Bernard, Leveziel, Nicolas, Coscas, Gabriel, Soubrane, Gisele, Souied, Eric H
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2010
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2909886/
https://ncbi.nlm.nih.gov/pubmed/20668719
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items